舍曲林联合大剂量丁螺环酮治疗难治性强迫症对照研究

A Control Study of Sertraline Combined with Buspar in Treatment of Refractory Obsessive-compulsive Disorder

目的:探讨舍曲林联合大剂量丁螺环酮治疗难治性强迫症的临床疗效和安全性。方法:将60例难治性强迫症患者随机分为合并组和单用组各30例,两组均口服舍曲林治疗,合并组联合丁螺环酮治疗,疗程12周。采用Yale-Brown强迫症状量表(Y-Brown),汉密尔顿焦虑量表(HAMA)评定临床疗效,症状量表(TESS)评定安全性。结果:治疗12周末,合并组有效率为70.0%,显著高于单用组的46.7%(P<0.05)。两组Y-Brow和HAMA量表评定均较治疗前显著下降(P<0.01),治疗4、6、8、12周末合并组评分均较单用组显著下降(P<0.05)。两组TESS评分差异无统计学意义(P>0.05)。结论:舍曲林联合大剂量丁螺环酮治疗难治性强迫症疗效显著,起效快,安全性高。

Objective：To explore the efficacy and safety of sertraline combined with buspar in treatment of refractory obsessive-compulsive disorder.Method：60 patients were randomly assigned to buspar groups（combinied used group）and sertraline group（single used group）treat for 12 weeks.Efficacies were assessed with the Yale-Brown Obsessive Compulsive Scale（Y-BOCS）,Hamilton anxiety scale（HAMA）and adverse reactions with the Tteatment Emergent Symptom Scale（TESS）at baseline and at the end of the 4,6,8,12 week.Result：The overall effective rate of buspar group（70.0%）was significantly higher than that of sertraline group（46.7%）（P〈0.05）.Between two groups the 12th week after the treatment,there were significant differences of the scores of Y-BOCS,HAMA（P〈0.05）,but no significant differences of the scores of TESS（P〉0.05）.There were no signifcant diifference of the rate of adverse reaction between two groups.Conclusion：Sertraline combined with buspar has notable advantages in efficacy and safety over single setraline in the treatment of refractory obsessive-compulsive disorder.